Brought to you by Procopio LLP and UC San Diego Institute for the Global Entrepreneur

Don’t miss this lunch and learn seminar designed to provide international life sciences companies with a practical overview of key legal considerations for entering and operating in the U.S. market. Topics will include U.S.-focused approaches to venture financing and deal structures, data privacy and regulatory compliance, and protecting and leveraging intellectual property in a highly competitive landscape.

Designed for companies exploring cross-border growth, the session will offer actionable insights to help navigate common challenges, mitigate risk, and position your business for success in the United States.

Session 1 | Early-Stage Deals: The U.S. Approach
Presented by Paul Johnson, Partner, Procopio LLP
This session will focus on key U.S. corporate and financing considerations for life sciences companies, with an emphasis on early-stage investment structures. Topics will include the benefits and requirements of Qualified Small Business Stock (QSBS), as well as an overview of commonly used financing instruments such as convertible notes and SAFEs. Attendees will gain practical insight into how these tools are used in the U.S. market and what international companies should consider when structuring investments and engaging with U.S. investors.

Session 2 | Data Privacy & U.S. Regulatory Compliance
Presented by Elaine Harwell, Partner & Privacy Officer, Procopio LLP
Gain a practical overview of the U.S. data privacy landscape and how it impacts life sciences companies entering the market. This session will cover key federal and state privacy frameworks, including health data considerations, enforcement trends, and compliance strategies for handling sensitive information. Attendees will leave with actionable guidance on mitigating risk, structuring data practices, and aligning with evolving U.S. privacy expectations.

Session 3 | Investor-Ready IP: U.S. Due Diligence Essentials
Presented by Frank Yang, Partner & Life Sciences Practice Group Co-Leader, Procopio LLP
This session will focus on the critical role of intellectual property due diligence in U.S. venture financing for life sciences companies. We will cover what investors look for when evaluating IP portfolios, common red flags that can impact valuation or delay deals, and steps companies can take to prepare in advance. Attendees will gain practical insights into aligning their IP strategy with investor expectations to support successful fundraising in the U.S. market.

Seats are extremely limited- reserve your spot today! Lunch is included.